Synthesis of pyrrolo[2,3-d]pyridazinones as potent, subtype selective PDE4 inhibitors

References

• Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998; 157: 351–370
   PubMed Web of Science ®Google Scholar
• Houslay MD. PDE4 cAMP-specific phosphodiesterases. Prog Nucleic Acid Res Mol Biol 2001; 69: 249–315
   PubMed Web of Science ®Google Scholar
• Dal Piaz V, Giovannomi MP. Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies. Eur J Med Chem 2000; 35: 463–480
   PubMed Web of Science ®Google Scholar
• Bousquet J, Chanez P, Vignola AM, Lacoste JY, Michel FB. Eosinophil inflammation in asthma. Am J Respir Crit Care Med 1994; 150: S33–S38
   PubMed Web of Science ®Google Scholar
• Whelan CJ. Inhibition of PAF-, LPS-, and cytokine-induced granulocyte accumulation in guinea pig lung by dexamethasone: Evidence that inhibition of IL-5 release is responsible for the selective inhibition of eosinophilia by glucocorticoids in guinea-pigs. Inflamm Res 1996; 45(4)166–170, Apr;
   PubMed Web of Science ®Google Scholar
• Nyman U, Mussener A, Larsson E, Lorentzen J, Klareskog L. Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor. Rolipram Clin Exp Immunol 1997; 108: 415–419
   PubMed Web of Science ®Google Scholar
• Spina D. Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs 2003; 63: 2575–2594
   PubMed Web of Science ®Google Scholar
• Hanifin JM, Chan SC, Cheng JB, Tofte SJ, Henderson WRJr, Kirby DS, Weiner ES. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol 1996; 107: 51–56
   PubMed Web of Science ®Google Scholar
• Muller T, Engels P, Fozard JR. Subtypes of the type 4 cAMP phosphodiesterases: Structure, regulation and selective inhibition. TIPS 1996; 17: 294–298
   PubMed Web of Science ®Google Scholar
• Schneider HH, Schmiechen R, Brezinski M, Seidler J. Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur J Pharmacol 1986; 127: 105–115
   PubMed Web of Science ®Google Scholar
• Souness JE, Rao S. Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal 1997; 9: 227–236
   PubMed Web of Science ®Google Scholar
• Kaulen P, Bruning G, Schneider HH, Sarter N, Baumgarten HG. Autoradiographic mapping of a selective cyclic adenosine monophosphate phosphodiesterase in rat brain with the antidepressant [3H]rolipram. Brain Res 1989; 503: 229–245
   PubMed Web of Science ®Google Scholar
• Buckle DR, Arch JR, Connolly BJ, Fenwick AE, Foster KA, Murray KJ, Readshaw SA, Smallridge M, Smith DG. Inhibition of cyclic nucleotide phosphodiesterase by derivatives of 1,3-bis(cyclopropylmethyl)xanthine. J Med Chem 1994; 37(4)476–485
   PubMed Web of Science ®Google Scholar
• Larson LJ, Pino MV, Geiger LE, Simeone CR. The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in rats. Pharmacol Toxicol 1996; 78: 44–49
   PubMedGoogle Scholar
• Burnouf C, Pruniax MP. Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs. Curr Pharm Des 2002; 8: 1255–1296
   PubMed Web of Science ®Google Scholar
• Christensen SB, Guider AM, Forster CJ, Gleason JG, Bender PE, Karpinski JM, DeWolf WE, Barnette MS, Underwood DC, Griswold DE, Cielinski LB, Burman M, Bochnowicz S, Osborn RR, Manning CD, Grous M, Hillegas LM, Bartus JO, Ryan MD, Eggleston DS, Haltiwanger RC, Torphy TJ. 1,4-Cyclohexanecarboxylates: Potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma. J Med Chem 1998; 41: 821–835
   PubMed Web of Science ®Google Scholar
• Barnette MS, Christensen SB, Essayan DM, Grous M, Prabhakar U, Rush JA, Kagey-Sobotka A, Torphy TJ. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: In vitro anti-inflammatory actions. J Pharmacol Exp Ther 1998; 284: 420–426
   PubMed Web of Science ®Google Scholar
• Karish SB, Gagnon JM. The potential role of roflumilast: The new phosphodiesterase-4 inhibitor. Ann Pharmacother 2006; 40(6)1096–1104
   PubMed Web of Science ®Google Scholar
• Hatzeman A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001; 297: 267–279
   PubMed Web of Science ®Google Scholar
• Perry MJ, O'Connell J, Walker C, Crabbe T, Baldock D, Russell A, Lumb S, Huang Z, Howat D, Alle R, Merriman M, Walls J, Daniel T, Hughes B, Laliberte F, Higgs GA, Owens RJ. CDP840: A novel inhibitor of PDE-4. Cell Biochem Biophys 1998; 29: 113–132
   PubMedGoogle Scholar
• Aoki M, Fukunaga M, Sugimoto T, Hirano Y, Kobayashi M, Honda K, Yamada T. Studies on mechanisms of low emetogenicity of YM976, a novel phosphodiesterase type 4 inhibitor. J Pharmacol Exp Ther 2001; 298: 1142–1149
   PubMed Web of Science ®Google Scholar
• Compton CH, Gubb J, Nieman RB, Edelson J, Amit O, Bakst A, Ayres JG, Creemers JPHH, Schultze-Werninghaus G, Brambilla C, Barnes NC. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: A randomised, dose-ranging study. Lancet 2001; 358: 265–270
   PubMed Web of Science ®Google Scholar
• Bateman ED, Izquierdio JL, Harnest U, Hofbauer P, Magvar P, Schmid-Wirlitsch C, Leichtl S, Bredenbroker D. Efficacy and safety of roflumilast in the treatment of asthma. Ann Allergy Asthma Immunol 2006; 96: 679–686
   PubMed Web of Science ®Google Scholar
• Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005; 365: 167–175
   PubMed Web of Science ®Google Scholar
• Harbinson PL, MacLeod D, Hawksworth R, O'Toole S, Sullivan PJ, Kilfeather S, Page CP, Costello J, Holgate ST, Lee TH. The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. Eur Respir J 1997; 10: 1008–1014
   PubMed Web of Science ®Google Scholar
• Alexander RP, Warrellow GJ, Eaton MAW, Boyd EC, Head JC, Porter JR, Brown JA, Reuberson JT, Hutchinson B, Turner P, Boyce B, Barnes D, Mason B, Cannell A, Taylor JR, Zomaya A, Millican A, Leonard J, Morphy R, Wales M, Allen RA, Gozzard N, Hughes B. CDP840. A prototype of a novel class of orally active anti-inflammatory phosphodiesterase 4 inhibitors. Bioorg Med Chem Lett 2002; 12: 1451–1456
   PubMed Web of Science ®Google Scholar
• Aoki M, Kobayashi M, Ishikawa J, Saita Y, Terai Y, Takayama K, Miyata K, Yamada T. A novel phosphodiesterase type 4 inhibitor, YM976 (4-(3-chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one), with little emetogenic activity. J Pharmacol Exp Ther 2000; 295: 255–260
   PubMed Web of Science ®Google Scholar
• Hersperger R, Bray-French K, Mazzoni L, Muller T. Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: a novel class of potent and selective phosphodiesterase type 4D inhibitors. J Med Chem 2000; 43: 675–682
   PubMed Web of Science ®Google Scholar
• Robichaud A, Stamatiou PB, Jin SLC, Lachance N, MacDonald D, Lalibertè F, Liu S, Huang Z, Conti M, Chan CC. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest 2002; 110: 1045–1052
   PubMed Web of Science ®Google Scholar
• Dal Piaz V, Ciciani G, Turco G. Oxidative cleavage of 7-oxo-6,7-dihydroisoxazolo[3,4-d]pyridazines by cerium(IV) ammonium nitrate. A synthetic approach to new 5-acyl-4-nitro-3-oxo-2,3-dihydropyridazines. Synthesis 1989; 3: 213–214
   Google Scholar
• Dal Piaz V, Ciciani G, Giovannoni MP. Synthesis of 4,5-functionalized-2-methyl-6-(substituted aryl)-3 (2H)-pyridazinones: A new group of potent platelet aggregation inhibitors. Il Farmaco 1997; 52: 173–178
   PubMedGoogle Scholar
• Renzi G, Dal Piaz V, Musante C. Condensation between b-oxobenzoyl compounds and hydroximic chloride. Gazz Chim Ital 1968; 98: 656–666
   Google Scholar
• Renzi G, Pinzauti S. New derivatives of isoxazolo[3,4-d]pyridazin-7(6H)-one. Il Farmaco Ed Sci 1969; 24: 885–889
   PubMedGoogle Scholar
• Dal Piaz V, Ciciani G, Giovannoni MP, Franconi F. Synthesis and evaluation as platelet aggregation inhibitors of 6-phenyl-2,4-substituted-3(2H)-pyridazinones and their rigid analogues benzo[h]cinnolin-3,5-diones. Drug Des Disc 1996; 14: 53–75
   PubMedGoogle Scholar
• Adams J, Hauser CR. Condensations. XXIX. Acylation of ketones with aliphatic anhydrides by means of BF3. Synthesis of β-diketones. J Am Chem Soc 1945; 67: 284–286
   Web of Science ®Google Scholar
• Gristwood RW, Beleta J, Bou J, Cardelus I, Fernandez AG, Lenas J, Berga P. Studies on the cardiac actions of flosequinam in vitro. Br J Pharmacol 1992; 105: 985–991
   PubMed Web of Science ®Google Scholar
• Thompson WJ, Strada SJ. Method of Enzymatic Analysis3th ed., HU Bergmayer. Verlag-Chemie, Weinheim 1984; IV: 127–134
   Google Scholar
• Percival MD, Yeh B, Falgueyret JP. Zinc dependent activation of cAMP-specific phosphodiesterase (PDE4A). Biochem. Biophys Res Commun 1997; 241: 175–180
   PubMed Web of Science ®Google Scholar
• Schneider HH, Schmiechen R, Brezinski M, Seidler J. Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur J Pharmacol 1986; 127: 105–115
   PubMed Web of Science ®Google Scholar
• Gantner F, Kupferschmitd R, Schudt C, Wendel A, Hatzelmann A. In vitro differentiation of human monocytes to macrophages: Change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors. Br J Pharmacol 1997; 121: 221–231
   PubMed Web of Science ®Google Scholar